rs6885099 — PDE8B PDE8B TSH variant
Intronic TSH quantitative trait locus in phosphodiesterase 8B — the G allele raises the thyroid set-point, increasing hypothyroidism risk and potentially affecting levothyroxine dose requirements
Details
- Gene
- PDE8B
- Chromosome
- 5
- Risk allele
- G
- Clinical
- Risk Factor
- Evidence
- Strong
Population Frequency
Category
Hormones & SleepSee your personal result for PDE8B
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
PDE8B — The Phosphodiesterase That Sets Your Thyroid's Thermostat
Your thyroid gland operates like a thermostat: the pituitary hormone
TSH (thyroid-stimulating hormone)11 TSH (thyroid-stimulating hormone)
Thyrotropin — secreted by the
anterior pituitary, it binds TSH receptors on thyroid follicular cells
and drives synthesis and release of T3 and T4. The pituitary adjusts
TSH output based on feedback from circulating thyroid hormone
levels signals the
thyroid to produce more or less hormone. But the gain on that thermostat
varies between individuals — and PDE8B is a key control knob.
PDE8B encodes phosphodiesterase 8B22 phosphodiesterase 8B
A cyclic nucleotide
phosphodiesterase highly expressed in thyroid tissue that specifically
degrades cAMP (cyclic adenosine monophosphate). cAMP is the second
messenger through which TSH stimulates thyroid hormone
production an enzyme that
degrades cAMP inside thyroid follicular cells. When TSH binds its
receptor, it triggers a cAMP surge that drives thyroid hormone synthesis.
PDE8B acts as a brake on that surge: higher PDE8B activity → faster
cAMP degradation → weaker thyroid response to TSH → the pituitary
compensates by raising circulating TSH levels. rs6885099 sits in intron 1
of PDE8B and influences how much of this enzyme the thyroid makes.
The Mechanism
rs6885099 is an intronic
quantitative trait locus (QTL)33 quantitative trait locus (QTL)
A genetic variant that influences the
quantity of a measurable trait — here, serum TSH levels — without
altering protein structure. These variants typically act through
regulatory elements (enhancers, splicing signals) embedded within
introns or non-coding regions affecting PDE8B gene expression in
thyroid tissue. The G allele is associated with higher PDE8B activity or
expression, which accelerates cAMP degradation and raises the thyroid's
effective TSH threshold. The result is a genetically-programmed
upward shift in the individual's TSH set-point — circulating TSH is
chronically higher relative to tissue thyroid hormone levels.
Critically, this is not the same as thyroid disease: individuals with
GG or AG genotypes have a higher TSH set-point but are often euthyroid
(normal circulating T3/T4). However, they may tip into
subclinical hypothyroidism44 subclinical hypothyroidism
TSH above the upper reference range with
normal free T4 — the most common form of thyroid dysfunction,
affecting 4-10% of the general population and up to 20% of women
over 60 at lower absolute
levels of thyroid dysfunction, and when they do require levothyroxine
replacement, their genetically higher set-point may require a higher
dose to suppress TSH adequately.
The Evidence
The largest study to date is the
Rand et al. 202555 Rand et al. 2025
Rand SA et al. Genome-wide association study and
polygenic risk prediction of hypothyroidism. Nat Genet,
2025 meta-analysis in
113,393 hypothyroidism cases and 1,065,268 controls — identifying
350 associated loci. rs6885099-G showed one of the strongest signals
(beta = 0.10, p = 1×10⁻⁹³), confirming PDE8B as a major determinant
of hypothyroidism susceptibility.
The TSH-lowering effect of the A allele was established by
Porcu et al. 201366 Porcu et al. 2013
Porcu E et al. A meta-analysis of thyroid-related
traits reveals novel loci and gender-specific differences in the
regulation of thyroid function. PLoS Genet,
2013 in up to 26,420
euthyroid subjects: the rs6885099-A allele reduced log-TSH by
0.141 units (p = 2×10⁻²⁶), with a stronger effect in males
(beta −0.168, p = 3×10⁻³⁸) than females (beta −0.12, p = 6×10⁻²⁴),
suggesting partial sex-hormone modulation of PDE8B activity.
Soto-Pedre et al. 201777 Soto-Pedre et al. 2017
Soto-Pedre E et al. Replication confirms the
association of loci in FOXE1, PDE8B, CAPZB and PDE10A with thyroid
traits: a GoDARTS study. Pharmacogenet Genomics,
2017 confirmed the locus
in 1,703 hypothyroidism cases and 9,457 controls; PDE8B variants
collectively explained 6.8% of TSH variance.
Wade et al. 202588 Wade et al. 2025
Wade AN et al. Strength of Genetic Associations
with Thyrotropin Values Differs Between Populations with Similarity to
African and European Reference Populations. Thyroid,
2025 found that PDE8B
was not significantly associated with TSH in African-ancestry populations
despite strong effects in Europeans — an important caveat for
interpreting the result in non-European individuals.
Practical Actions
For GG and AG individuals, the main clinical implications are: (1) awareness of a higher baseline TSH that may require lower thresholds for hypothyroidism diagnosis, (2) for those already on levothyroxine, the TSH target may need adjustment relative to standard ranges, and (3) monitoring iodine intake — since thyroid hormone synthesis requires iodine, marginal iodine status combined with a high-PDE8B set-point amplifies hypothyroidism risk.
Selenium supports deiodinase enzymes99 deiodinase enzymes
Selenoproteins that convert
the storage form T4 to the active T3; selenium deficiency impairs this
conversion and may worsen functional hypothyroidism even when TSH
is only mildly elevated that convert inactive T4 to active T3.
GG carriers benefit specifically from ensuring selenium adequacy.
Interactions
rs4704397 (PDE8B intron 1) is in strong linkage disequilibrium with rs6885099 and captures overlapping variance. Both variants have been studied for TSH effects; their combined information adds little beyond either alone.
rs2046045 (PDE8B intron 1) is a third correlated variant in the same LD block, consistently identified in GWAS of TSH and hypothyroidism.
rs11206244 (TPO — thyroid peroxidase) affects thyroid hormone synthesis directly rather than cAMP signaling, acting through a different pathway. Individuals combining a high PDE8B set-point (this SNP) with impaired TPO activity may have compounded hypothyroidism risk.
Drug Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Reference alleles — lower TSH set-point, reduced hypothyroidism risk
In the Porcu et al. 2013 meta-analysis of 26,420 euthyroid subjects, the A allele was associated with a −0.141 log-unit reduction in TSH per allele (p = 2×10⁻²⁶). In the Rand et al. 2025 Nature Genetics hypothyroidism GWAS, the A allele was protective against hypothyroidism (beta = −0.10, p = 1×10⁻⁹³ for the G allele). AA homozygotes have the lowest genetically-programmed TSH set-point of the three genotypes.
This does not guarantee normal thyroid function — TSH is influenced by many genes, nutritional status, autoimmunity, and age. But at this specific locus, your genetic contribution pushes toward lower TSH and reduced risk of hypothyroidism.
One risk allele — mildly elevated TSH set-point
Under the additive inheritance model confirmed by multiple GWAS, each G allele contributes independently to higher TSH levels. AG carriers sit midway between the low set-point of AA and the high set-point of GG. In European populations, the G allele frequency is approximately 0.40, making AG the modal genotype.
The elevated set-point is typically within normal TSH reference ranges (0.4–4.0 mU/L) but sits higher within that range. This increases the probability of crossing into subclinical hypothyroidism (TSH > 4.0–4.5 mU/L) during periods of thyroid stress — iodine deficiency, autoimmune challenge, pregnancy, or aging. The Rand et al. 2025 GWAS confirmed that the PDE8B locus effect on hypothyroidism risk is additive.
For individuals already on levothyroxine, an AG genotype at this locus may mean that the TSH target needed to feel well is in the lower-normal range rather than mid-range.
Two risk alleles — elevated TSH set-point, increased hypothyroidism susceptibility
The GG genotype means your thyroid cells degrade cAMP more efficiently after TSH stimulation, blunting the hormone production response. To compensate, your pituitary secretes more TSH — chronically. This higher baseline TSH does not always cause symptoms or disease, but it narrows the margin before TSH crosses into the subclinical or overt hypothyroidism range.
In the Porcu et al. 2013 GWAS, the per-allele effect of G on log-TSH was +0.141 units (additive), meaning GG homozygotes have approximately +0.28 log-units higher TSH than AA individuals — roughly a 32% higher absolute TSH at the same level of thyroid function.
For individuals with GG genotype already on levothyroxine replacement: the genetically higher TSH set-point means the conventional TSH target (0.5–2.5 mU/L) may underestimate how much T4 your specific system requires. Multiple studies have documented that some patients on levothyroxine feel better — and show better metabolic markers — when TSH is maintained in the lower third of the reference range. Your GG genotype is one reason your treating physician might aim for a TSH target of 0.5–1.5 mU/L rather than 2.0–4.0 mU/L.
Note: the PDE8B effect on TSH is attenuated in African-ancestry individuals (Wade et al. 2025), so the magnitude of this risk prediction is most applicable to those of European descent.